Lantern Pharma Inc.
NASDAQ:LTRN
3.42 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.175 | 0.155 | 0.097 | 0.003 | 0.002 | -0.003 |
| Gross Profit
| -0.175 | -0.155 | -0.097 | -0.003 | -0.002 | 0.003 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 11.894 | 8.603 | 7.571 | 2.243 | 0.953 | 0.572 |
| General & Administrative Expenses
| 5.983 | 5.83 | 5.021 | 3.665 | 1.475 | 1.154 |
| Selling & Marketing Expenses
| -5,977.447 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.983 | 5.83 | 5.021 | 3.665 | 1.475 | 1.154 |
| Other Expenses
| -0 | -0.032 | 0.161 | 0 | 0 | 0 |
| Operating Expenses
| 17.878 | 14.433 | 12.592 | 5.908 | 2.428 | 1.726 |
| Operating Income
| -17.878 | -14.433 | -12.592 | -5.908 | -2.428 | -1.726 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.916 | 0.173 | 0.228 | 0 | -0 | 0 |
| Income Before Tax
| -15.962 | -14.26 | -12.363 | -5.908 | -2.428 | -1.726 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0 | -0.173 | -0.068 | -0.203 | -0 | 0.003 |
| Net Income
| -15.962 | -14.087 | -12.295 | -5.908 | -2.428 | -1.726 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.47 | -1.3 | -1.13 | -0.95 | -0.39 | -0.28 |
| EPS Diluted
| -1.47 | -1.3 | -1.13 | -0.95 | -0.39 | -0.28 |
| EBITDA
| -17.863 | -14.423 | -12.585 | -5.905 | -2.427 | -1.726 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |